This way, the p38–Claspin pathway protects cells from DNA damage occurring during the S-phase [69], representing another resistance mechanism to cisplatin and, therefore, a potentially targetable pathway for cancer treatment [69]. This evidence concerns the gene CLSPN and cancer.